Ann: Important GSK initiatives to new influenza A, page-2

re: Ann: Important GSK initiatives to new inf... You can bet GSK wouldn't be sticking their necks out on 60m units a year without a firm market demand in mind so this will definitely translate into sales over the next 12 months. Assuming say A$40 a unit that's over $2 billion in sales and at least A$140m pa in royalties, way beyond Biota's ability to comprehend or cope. Bound to be a takeover offer. Plenty of struggling biotechs would love that kind of revenue stream.